Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Patrick Harrison Carroll sold 23,287 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total value of $798,976.97. Following the sale, the insider now owns 209,661 shares of the company’s stock, valued at approximately $7,193,468.91. This trade represents a 10.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Hims & Hers Health Trading Down 3.0 %
HIMS opened at $32.85 on Friday. The stock has a market cap of $7.30 billion, a PE ratio of 74.67 and a beta of 1.37. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98. The stock’s 50 day simple moving average is $39.02 and its 200-day simple moving average is $28.55.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.
Institutional Trading of Hims & Hers Health
Wall Street Analyst Weigh In
Several research firms recently weighed in on HIMS. Truist Financial boosted their target price on Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a report on Wednesday, February 26th. BTIG Research assumed coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Leerink Partners raised their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday, February 25th. Bank of America boosted their target price on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a research report on Tuesday. Finally, Canaccord Genuity Group increased their target price on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and a consensus price target of $37.31.
Read Our Latest Report on HIMS
Hims & Hers Health Company Profile
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
See Also
- Five stocks we like better than Hims & Hers Health
- What is Short Interest? How to Use It
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- How to Short Nasdaq: An Easy-to-Follow Guide
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- 3 Best Fintech Stocks for a Portfolio Boost
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.